Sorafenib (SOR), a frontline hepatocellular carcinoma (HCC) therapeutic, induces ferroptosis through inhibition of solute carrier family 7 member 11 (SLC7A11). The gene discussed is SLC7A11; the disease is hepatocellular carcinoma.